San Diego-based Mapp Biopharmaceutical's ZMapp is one of four experimental drugs being tested in the Democratic Republic of Congo, and although it was used during the West African Ebola epidemic, data was insufficient to determine its efficacy in preventing people from being infected with the virus. This time ZMapp, mAb114, Gilead Sciences' Remdesivir and Regeneron's REGN-EB3 are being used at the country's Ebola hot spots in Beni and Butembo, where researchers are trying to gain more data despite challenges they are encountering due to violence and unrest.
Researchers risk dangers in Congo to test experimental Ebola drugs
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.